Published Date: 30-Sep-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Fill Finish Manufacturing Market size is expected to reach $16.1 billion by 2028, rising at a market growth of 9.5% CAGR during the forecast period.
The Contract Manufacturing Organizations segment is showcasing a CAGR of 9.7% during (2022 - 2028). To avoid the acronym misunderstanding of Chief Medical Officer or Clinical Monitoring Organization in the pharmaceutical industry, contract manufacturing organizations (CMOs) have been referred to as contract development and manufacturing organizations (CDMOs) more recently (and more frequently now).
The Consumables segment acquired maximum revenue share in the Global Fill Finish Manufacturing Market by Product in 2021 thereby, achieving a market value of $9.4 billion by 2028. It is due to the elements such as expanding disposable biologics packaging use and rising demand for prefilled syringes. Consumables have a shorter shelf life than instruments and are used much more frequently as a result.
The Europe market dominated the Global Fill Finish Manufacturing Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $5.3 billion by 2028. The North America market is exhibiting a CAGR of 9.1% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 10.3% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Becton, Dickson, and Company, Gerresheimer AG, Syntegon Technology GmbH, West Pharmaceutical Services, Inc., OPTIMA packaging group GmbH, IMA Group, Marchesini Group S.p.A., Nipro Corporation, Schott AG (Carl-Zeiss-Stiftung), and SGD Pharma.
By End User
Unique Offerings from KBV Research